Gadopentetic acid


Concise Prescribing Info
Indications/Uses
Cranial, spinal and whole body imaging.
Dosage/Direction for Use
Adult : IV As gadopentetate dimeglumine: 0.1 mmol/kg (0.2 mL/kg), given at a rate not exceeding 10 mL/15 sec. If needed, an additional dose of 0.1-0.2 mmol/kg over 30 minutes may be given. Max: 0.3 mmol/kg.
Dosage Details
Intravenous
Cranial, spinal and whole body imaging
Adult: As gadopentetate dimeglumine: 0.1 mmol/kg (0.2 mL/kg), given at a rate not exceeding 10 mL/15 sec. If needed, an additional dose of 0.1-0.2 mmol/kg over 30 minutes may be given. Max: 0.3 mmol/kg.
Child: ≥1 month As gadopentetate dimeglumine: 0.1 mmol/kg (0.2 mL/kg), given at a rate not exceeding 10 mL/15 sec; >1 year If needed, additional dose of 0.1-0.2 mmol/kg over 30 minutes may be given.
Renal Impairment
Severe (GFR <30 mL/min/1.73 m2): Contraindicated.
Contraindications
Hypersensitivity. Acute kidney injury, patient in perioperative liver transplantation period. Severe renal impairment (GFR <30 mL/min/1.73 m2). Neonates <4 week.
Special Precautions
Patient with history of allergic reactions, bronchial asthma, seizure disorders, intracranial lesions. Mild to moderate renal impairment. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Gadolinium retention, extravasation reactions (e.g. thrombosis, skin and soft tissue necrosis). Rarely, seizures.
Gastrointestinal disorders: Nausea, vomiting, dysgeusia.
Injury, poisoning and procedural complications: Inj site reactions (e.g. pain, oedema, irritation).
Nervous system disorders: Headache, dizziness.
Skin and subcutaneous tissue disorders: Hot or cold sensation.
Potentially Fatal: Nephrogenic systemic fibrosis. Rarely, hypersensitivity (e.g. anaphylactic reactions).
MonitoringParameters
Monitor renal function prior to administration. Monitor for signs and symptoms of hypersensitivity reactions, extravasation, nephrogenic systemic fibrosis (e.g. muscle weakness, rib bone pain).
Lab Interference
Falsely low value result with serum Fe determination test using complexometric methods.
Action
Description: Gadopentetic acid is an ionic gadolimium chelate, paramagnetic contrast media for MRI. It shortens the relaxation time of water protons in the plasma leading to increase in signal intensity, thus enhancing the image contrast between tissues.
Pharmacokinetics:
Distribution: Rapidly distributed into the extracellular space. Crosses placenta and enters breast milk in small amount. Volume of distribution: Approx 0.266 ± 0.043 L/kg.
Excretion: Via urine (approx 91% as gadopentetate). Elimination half-life: 1.6 ± 0.13 hr.
Chemical Structure

Chemical Structure Image
Gadopentetic acid

Source: National Center for Biotechnology Information. PubChem Database. Gadopentetate, CID=6857474, https://pubchem.ncbi.nlm.nih.gov/compound/Gadopentetate (accessed on Jan. 22, 2020)

Storage
Store between 15-30°C. Do not freeze. Protect from light.
ATC Classification
V08CA01 - gadopentetic acid ; Belongs to the class of paramagnetic agents used as magnetic resonance imaging contrast media.
References
Anon. Gadopentetate Dimeglumine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/01/2018.

Buckingham R (ed). Gadopentetic Acid. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/01/2018.

Magnevist Injection (Bayer HealthCare Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/01/2018.

Disclaimer: This information is independently developed by MIMS based on Gadopentetic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in